Latest News for: her2
Edit
ENHERTU® Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer (Daiichi Sankyo Co Ltd)
Public Technologies 22 Jan 2026
Press Release ENHERTU®Approved in China as the First and Only HER2 Directed ADC for the Second-Line Treatment of Patients with HER2 Positive Metastatic Gastric Cancer ... About HER2 Positive Gastric Cancer ... only) is a HER2 directed ADC.
Edit
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Nasdaq Globe Newswire 20 Jan 2026
Edit
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage ...
Business Wire 20 Jan 2026
Edit
HER2-Negative Metastatic Breast Cancer Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight ...
GetNews 17 Jan 2026
To Know in detail about the HER2-Negative Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ... Since HER2 is not overactive, HER2-targeted therapies like trastuzumab are ineffective.
Edit
The Galveston Daily News
12 Jan 2026
Bio-Sourcing and Zerion Pharma Join Forces to Develop First HER2 Oral Monoclonal Antibody Against Breast Cancer
The Galveston Daily News
12 Jan 2026
Edit
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
Nasdaq Globe Newswire 12 Jan 2026
Edit
HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by ...
GetNews 09 Jan 2026
... Cancer Symposium (SABCS) in December provided further insights into the use of trastuzumab deruxtecan (T-DXd; Enhertu; Daiichi Sankyo) across various stages of HER2-positive (HER2+) breast cancer.
Edit
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
Business Wire 07 Jan 2026
Edit
The Facts
06 Jan 2026
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including ...
The Facts
06 Jan 2026
Edit
Ziihera� (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including ...
Nasdaq Globe Newswire 06 Jan 2026
ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, ...
Edit
Bayer receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer (Bayer AG)
Public Technologies 06 Jan 2026
Edit
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
PR Newswire 06 Jan 2026
Edit
ENHERTU® Approved in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies (Daiichi Sankyo Co Ltd)
Public Technologies 25 Dec 2025
Press Release ENHERTU®Approved in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies.
Edit
The Facts
23 Dec 2025
Lunit SCOPE Demonstrates High Concordance with Pathologists in HER2 Interpretation for Advanced Biliary Tract Cancer
The Facts
23 Dec 2025
Study published in Laboratory Investigation, the official journal of the United States and Canadian Academy of Pathology ....
- 1
- 2
- Next page »
